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Tuberculosis (TB) remains a global pandemic, in both animals and man, and novel vaccines are urgently
required. Heterologous prime-boost of BCG represents a promising strategy for improved TB vaccines,
with respiratory delivery the most efﬁcacious to date. Such an approach may be an ideal vaccination
strategy against bovine TB (bTB), but respiratory vaccination presents a technical challenge in cattle. Inert
bacterial spores represent an attractive vaccine vehicle. Therefore we evaluated whether parenterally
administered spores are efﬁcacious when used as a BCG boost in a murine model of immunity against
Mycobacterium bovis.
Here we report the use of heat-killed, TB10.4 adsorbed, Bacillus subtilis spores delivered via subcu-
taneous injection to boost immunity primed by BCG. We demonstrate that this approach improves the
immunogenicity of BCG. Interestingly, this associated with substantial boosting of IL-17 responses;
considered to be important in protective immunity against TB. These data demonstrate that parenteral
delivery of spores represents a promising vaccine vehicle for boosting BCG, and identiﬁes potential for
optimisation for use as a vaccine for bovine TB.
Crown Copyright © 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) caused by infection with Mycobacterium
tuberculosis (M. tuberculosis) orMycobacterium bovis remains one of
the most important infectious diseases of man and animals,
respectively; inﬂicting a huge cost in both health, welfare and
ﬁnancial terms [1]. At present the only available vaccine against TB
is M. bovis bacille CalmetteeGuerin (BCG), which demonstrates
variable efﬁcacy in humans and cattle [2,3]. In humans in particular,
BCG induces some protection against childhood disseminated TB
and tuberculous meningitis, but poor protection against pulmonary
TB in adolescents and adults [4]. Despite this inconsistent perfor-
mance, BCG remains the most widely used human vaccine in the; fax: þ44 1932 357260.
. Kaveh).
ion, Public Health England,
vier Ltd. This is an open access artiworld and due to its partial efﬁcacy and proven safety record, is
unlikely to be withdrawn. Hence, a great deal of research effort is
targeted toward improving the efﬁcacy of BCG by a number of
approaches; prominent among which is boosting BCG with heter-
ologous vaccines [5,6]. Although respiratory delivery appears to
provide the most efﬁcacious boost (reviewed in [7]), this may not
be practical for a cattle vaccination strategy against bovine TB (bTB).
Optimal protection against TB requires CD4 T cells, as well as the
effector cytokines IFN-g and TNF-a (reviewed in Ref. [8]). However,
studies have demonstrated, CD4 T cell derived IFN-g is not an
exclusive component of vaccine-mediated immunity [9] and
identiﬁcation of other critical components of protection remains
elusive. The role of CD8 T cells in protection against TB is somewhat
less clear and as yet poorly deﬁned [8].
A number of heterologous boost vehicles for tuberculosis vac-
cines have been evaluated and (reviewed in [10]). Inert bioparticles,
such as Bacillus subtilis spores, are effective delivery vehicles with
immunomodulatory properties [11,12], capable of inducing pro-
tective immunity against disease [13,14], including showingcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
M.C. Garcia-Pelayo et al. / Tuberculosis 98 (2016) 97e10398promise via respiratory vaccination against TB [15]. These data,
combined with the desirable properties of cost and scalability [16],
suggest B. subtilis spores may represent an ideal vehicle candidate
for boosting BCG in a vaccination strategy against bTB. As respira-
tory vaccination, however, remains a technical challenge in bovine
species, we wished to evaluate the potential of such spores as an
injectable BCG boost in a murine model of immunity against
M. bovis.
We chose to evaluate an ESAT-6 family protein, RV0288 (TB10.4)
[17] as a model antigen to adsorb onto heat-killed (HK) B. subtilis
spores as a subunit BCG boost vaccine against bTB. TB10.4 is highly
immuno-dominant in BCG immunised [18], and M. bovis infected
mice [19,20], and cattle [21]. As TB10.4 is expressed by both BCG
andM. bovis, it may therefore represent an ideal candidate in a BCG
boost strategy.
Here we report the use of inert, TB10.4 adsorbed, B. subtilis
spores delivered via subcutaneous injection (s.c) to boost immunity
previously primed by BCG, in a murine M. bovis challenge model.
We demonstrate that this approach induced signiﬁcant immuno-
logical boosting, most notably of TB10.4-speciﬁc IL-17, which is
considered to be important in protection against TB [22].
2. Materials & methods
2.1. Animals
Female BALB/c mice were obtained from SPF facilities at Charles
River UK Ltd. and used at 8 weeks of age. All animals were housed
in appropriate BSL3/SAPO 4 containment facilities at APHA. After
challenge with M. bovis, all mice were weighed twice weekly and
assessed for clinical signs of tuberculosis daily.
2.2. Strains and antigens
HU58 is a non-domesticated strain of B. subtilis isolated from the
human gastrointestinal (GI) tract [23]. The BCG vaccination strain
was the human vaccine M. bovis BCG Danish 1331 prepared as per
manufacturer's instructions (SSI, Copenhagen, Denmark). M. bovis
strain AF2122/97 was used for all challenge experiments as
described [19]. Recombinant mycobacterial protein TB10.4 (Proteix
sro., Prague, Czech Republic) was used for stimulation as described
previously [19].
2.3. Antisera
Polyclonal sera reactive to TB10.4 was obtained from previous
experiments. Brieﬂy, mice were immunised three times at two
week intervals with 10 mg TB10.4 emulsiﬁed in MPL/DDA adjuvant.
Pooled serumwas prepared from terminal cardiac bleeds taken two
weeks after ﬁnal immunisation.
2.4. Production of B. subtilis spores
Strains were routinely grown in Difco sporulation medium
(DSM, Difco, UK), and spores were prepared in large quantities
using growth on solid DSM [24]. Spores were washed and puriﬁed
before use, and aliquots were stored at 20 C until use. For
preparation of HKHU58 spores, theywere autoclaved (121 C,15 lb/
in2, 30 min) before use.
2.5. Adsorption of proteins onto spores
Suspensions containing 2  109 spores were centrifuged, and
pellets were suspended in 0.2 ml of 0.01 M PBS at pH 4, 7, or 10.
Puriﬁed proteins (10 mg) were added to the spore suspension, andthe binding mixture was incubated for 30 min at RT. Spores were
centrifuged, and the pellet was washed twice with PBS (at the same
pH as that in the binding mixture). Adsorption was evaluated by
extraction and solubilisation of adsorbed proteins. Spore coat
protein extractions were done as described previously [25] by
suspending the spore pellet in spore coat extraction buffer, incu-
bation at 68 C for 1 h, and gel electrophoresis, followed by
detection of bound protein by Western blotting using TB10.4
reactive sera.
2.6. Immunisation, mycobacterial enumeration and challenge
There were six separate treatment groups (n ¼ 22) of mice:
Placebo; BCG; BCG/Spore-TB10.4; BCG/Spore-empty; Spore-TB10.4
and Spore-empty. Groups of mice were immunised with a single
intradermal (i.d.) injection (50 ml) containing 2  105 CFU of BCG or
PBS placebo, in the base of the tail. Six weeks later groups of pla-
cebo or BCG immunised mice were boosted twice subcutaneously
(s.c. 50 ml) with 1010 TB10.4 adsorbed (1.5 mg TB10.4/dose) B. subtilis
spores (Spore-TB10.4) or control spores (Spore-empty), four weeks
apart. Four weeks later, six mice per group were euthanised for
immunological analyses, and all remaining mice were challenged
via intranasal route (i.n.) with ~300 CFU M. bovis as described
previously [26]. Four weeks later, 6e8 mice/group were euthan-
ised, lungs and spleens removed, homogenised, serially diluted and
plated out onto modiﬁed Middlebrook 7H11 agar medium [27].
Bacterial colonies were enumerated four weeks later following
incubation at 37 C. For survival data, remaining mice (n ¼ 8) were
monitored for a further 318 days post-challenge, or until clinical
manifestations of TB necessitated euthanasia at a humane endpoint
according to a clinical scoring system.
2.7. Cell isolation and stimulation
Following euthanasia, spleens were aseptically removed and
cells prepared as previously described [19]. Following washing
(300 g/8 min), all cells were re-suspended at 5  106/ml for assays.
Cells were cultured with speciﬁc antigen as stated, with each in-
dividual protein or peptide antigen at a ﬁnal concentration of 2 mg/
ml for all assays.
2.8. IFN-g ELISPOT
Cells were incubated with TB10.4 protein, and the frequency of
antigen-speciﬁc IFN-g secretors detected by ELISPOT (Mabtech,
Stockholm, Sweden), as previously described [19].
2.9. Cytokine production
Cells (5  106/ml) were cultured in the presence of antigen for
72 h (37 C/5% CO2) prior to harvest of supernatant. Production of
IFN-g, TNF-a, IL-2, IL-4, IL-6, IL-10, IL-12, and IL-17wasmeasured by
multiplex chemi-luminescent ELISA using theMeso Scale Discovery
platform (MSD®, Rockville, Maryland) according to manufacturer's
instructions.
2.10. Flow cytometry
For intracellular cytokine staining (ICS), cells were stimulated
with TB10.4 antigen and anti-CD28 (BD Biosciences, Oxford, UK) as
previously described [19]. They were surface stained with pre-
titrated antibodies: CD4eBrilliant Violet (BV) 711, CD44eBV785,
CD62LeBV605, CD25-BV421, CD19-Alexa Fluor (AF) 700, TER119-
AF700 (all Biolegend, London, UK), CD8-APC-H7 (BD Bioscience),
CD16/32-AF700, CD27-PE and LIVE/DEAD® Fixable Yellow Dead
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cells were washed, ﬁxed/permeabilised and stained by ICS with
IFN-geAPC (BD Bioscience), IL-2ePE-Cy7 and TNF-aeFITC as pre-
viously described [19]. All antibody conjugates were purchased
from eBioscience (Hatﬁeld, UK) except where stated. Data were
acquired using a SORP LSR Fortessa (BD Bioscience) (utilising a
532 nm laser for PE and PE-Cy7) and analyzed on Flowjo v.10.0.7
(Tree Star, USA) software. All analyses were on a minimum of
100,000 live lymphocytes, gating on T cells with the exclusion of
CD19þ (B cells), CD16/32þ (FcgRþ) and TER119þ (RBC) cells utilising
a dump channel.
2.11. Statistical analysis
Non-survival data were analysed by 1-way ANOVA with Bon-
ferroni's post-hoc test, using GraphPad Prism 5 software (GraphPad,
USA). Prior to analysis, mycobacterial counts were log10 trans-
formed and ELISA/ELISPOT datawere normalised by subtracting the
unstimulated from the antigen-stimulated culture values. Survival
data was analysed with the ManteleCox Log Rank test. Differences
with a r < 0.05 (or r ¼ 0.06 for survival data) were considered
signiﬁcant and denoted with *; r < 0.01 with **; r < 0.001 with ***;
and r < 0.0001 with ****.
3. Results
3.1. TB10.4 adsorption onto the spores is unaffected by pH
TB.10.4, a highly immunogenic and protective M. tuberculosis
complex antigen, was adsorbed onto HK B. subtilis spores at various
pH ranging from 4 to 10. As can be observed in Figure 1, adhesion
onto the surface of spores was not affected by pH and so further
adsorption was performed at pH 7.
3.2. Spore-TB10.4 did not additionally boost IFN-g secreting cell
frequency following BCG immunisation
To assess the boosting effect of TB10.4 antigen-adsorbed spores
(Spore-TB10.4), BCG or placebo immunised mice (n ¼ 6) were
boosted six weeks after vaccination with two doses of either
Spore-TB10.4 or un-adsorbed spores (Spore-empty). In order to
ensure maximum effect, the common strategy (reviewed in [7]) of
two boosts was used. To establish immune status prior to chal-
lenge, one month after the ﬁnal vaccination, spleen cells from in-
dividual mice in each vaccine regimen were subjected to an IFN-g
ELISPOT assay (Figure 2). As shown in Figure 2, BCG induced sig-
niﬁcant responses compared to the placebo control immunisation
(469 vs 23 SFU, r < 0.001); but boosting BCG with either antigen-Figure 1. TB10.4 adsorption onto the spores is unaffected by pH. Puriﬁed suspensions
of heat killed B. subtilis spores in PBS buffers of different pHs were mixed with puriﬁed
recombinant TB10.4 protein and incubated for 30 min at RT. Spores were centrifuged,
and the pellet was washed twice and the absorbed proteins extracted. One tenth of the
extract was used for western blot analysis comparing against the puriﬁed protein and
unabsorbed empty spore.adsorbed spores (BCG/Spore-TB10.4, 477 vs 23 SFU, r < 0.001), or
control spores (BCG/Spore-empty, 387 vs 23 SFU, r < 0.05) failed to
further enhance the frequency of TB10.4-speciﬁc IFN-g secreting
cells.3.3. Spore-TB10.4 boosts speciﬁc BCG induced Th2 and Th17
responses, but not Th1
In order to further assess the immunological effects of boosting
BCG by antigen-adsorbed spores, antigen-speciﬁc (TB10.4) cytokine
responses were assayed in 3 day spleen cell cultures from indi-
vidual mice in the different vaccine regimens. As shown in Figure 3,
antigen-adsorbed spores boosted TB10.4-speciﬁc IL-4 (2.5 fold,
r < 0.01), IL-10 (2.5 fold, r < 0.001) and IL-17 (10 fold, r < 0.001)
cytokine production compared to BCG alone. This was largely
speciﬁc to the antigen-adsorbed, rather than empty control spores
(IL-4 r < 0.05, IL-10 r < 0.001, IL-17 r < 0.001: vs BCG/Spore-
TB10.4). For comparison, the effect of vaccination upon spleen
cell production of IFN-g and IL-12 (archetypal Th1 cytokines) is
shown, demonstrating that spore boosting had no effect upon IFN-
g or IL-12 production and therefore Th1 responses, concurring with
the IFN-g ELISPOT data in Figure 2.3.4. Spore boosting has no additional effect on BCG-induced
multifunctional (IFN-gþIL-2þTNF-aþ) CD4 or CD8 T cells
The capacity of Spore-TB10.4 to boost both CD4 and CD8 T cell
responses was interrogated by intracellular cytokine staining
(ICS) and ﬂow cytometry upon individual spleen cell cultures. As
described in Figure 4A, and previously reported [19,20], BCG (or
any regimen including BCG) induced a signiﬁcant frequency (all
r < 0.001 vs control) of IFN-gþIL-2þTNF-aþ multifunctional CD4
T cells (BCG: 0.148%; BCG/Spore-TB10.4: 0.116% and BCG/Spore-
empty: 0.088% of spleen CD4þ cells). The frequency of these
cells was not boosted by the spore-TB10.4 boost. By contrast, BCG
immunisation induces a poor antigen-speciﬁc CD8 T cell
response (BCG: 0.059% spleen CD8þ cells), and no boosting was
observed.Figure 2. Spore-TB10.4 did not boost frequency of IFN-g producing cells following BCG
immunisation. BCG immunised or placebo control mice (n ¼ 6) were boosted six weeks
after vaccination with two doses of either Spore-TB10.4 or Spore-empty, one month
apart. Four weeks after ﬁnal vaccination, spleen cells from individual mice in each
vaccine regimen were subjected to IFN-g ELISPOT assay after stimulation with the
same BCG-derived recombinant protein TB10.4. Bars represent the mean ± SEM.
*r < 0.05, **r < 0.01.
Figure 3. Spore-TB10.4 boosts speciﬁc BCG-induced Th2 and Th17 responses, but not Th1. BCG immunised or placebo control mice (n ¼ 6) were boosted six weeks after vaccination
with two doses of either Spore-TB10.4 or Spore-empty, one month apart. Four weeks after ﬁnal vaccination, spleen cells from individual mice in each vaccine regimenwere cultured
with the BCG-derived recombinant protein TB10.4, and three day supernatants assayed by chemiluminescent ELISA. Bars represent the mean ± SEM. *r < 0.05, **r < 0.01,
***r < 0.001.
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protection over BCG alone
In order to assess the protective efﬁcacy of these vaccine
regimens, one month after the last vaccination mice were
challenged intranasally with ~300 CFU of M. bovis. The bacterial
burden in spleen and lungs were assessed one month later in
individual mice (n ¼ 6e8). As shown in Figure 5, this challenge
results in a substantial M. bovis burden of: 4.27 Log10 CFU in the
spleen and 6.31 Log10 CFU in the lungs of placebo control mice.
The protection induced by BCG was a reduction of 1.38 Log10 CFU
in the spleen (r < 0.001) and 1.75 Log10 CFU in the lungs
(r < 0.0001).
The addition of the spore-TB10.4 boost to BCG did display a
trend for reduced bacterial burden (0.93 Log10 CFU in the spleen
and 0.54 Log10 CFU in the lungs) compared to BCG alone. Although
this was not statistically signiﬁcant, it did approach this in the
spleen (r < 0.057). These two separate doses of spore-TB10.4 in the
absence of BCG failed to induce any signiﬁcant protection
compared to the placebo controls.3.6. BCG/spore-TB10.4 heterologous prime-boost did not increase
long-term survival over BCG alone
In order to assess the long-term protection induced by vacci-
nation, all remainingmice (n¼ 7/8) were kept for a further 318 days
post-challenge, or until clinical manifestations of TB necessitated
euthanisation according to a clinical scoring system. Survival,
therefore, was counted as the time to humane endpoint. Because of
technical issues, these mice were housed at Speciﬁc Animal Path-
ogen Order (SAPO, HSE, UK) Level 4, which precluded any sampling
of these animals for histology or bacterial counts. As shown in
Figure 6, placebo controls had a Median Survival Time (MST) of 188
days, whilst BCG increased the survival to an MST of 285 days
(r ¼ 0.06). BCG/spore-TB10.4 vaccination failed to further increase
survival (MST ¼ 263 days).4. Discussion
Boosting BCG via heterologous prime-boost remains the most
promising mid-term scenario for improved TB vaccination [6,7].
Figure 4. Spore boosting has no additional effect on BCG-induced multifunctional
(IFN-gþIL-2þTNF-aþ) CD4 or CD8 T cells. BCG immunised or placebo control mice
(n ¼ 6) were boosted six weeks after vaccination with two doses of either Spore-TB10.4
or Spore-empty, one month apart. Four weeks after ﬁnal vaccination, spleen cells from
individual mice in each vaccine regimen were stimulated with the BCG-derived re-
combinant protein TB10.4, stained by intracellular cytokine staining (ICS) and inter-
rogated by ﬂow cytometry. Graphs represent the percentage of live CD4þ (A) and CD8þ
(B) lymphocytes detected in the analysis, as determined by the inclusion of a LIVE/
DEAD ﬁxable yellow dead cell stain. Cells were analysed for all combinations of
simultaneous IFN-g, IL-2 and TNF-a production. Bars represent the mean ± SEM.
****r < 0.0001 cf. controls.
Figure 5. BCG/spore-TB10.4 heterologous prime boost did not increase protection over
BCG alone. BCG immunised or placebo control mice were boosted six weeks after
vaccinationwith two doses of either Spore-TB10.4 or Spore-empty, onemonth apart. Four
weeks after ﬁnal vaccination micewere challenged intranasally with ~300 CFU ofM. bovis
and Spleen and Lungs from individual mice were removed four weeks following chal-
lenge and bacteria enumerated. Data represent the mean bacterial burden per organ ± SE.
**r < 0.01; ***r < 0.001; ****r < 0.0001 cf. control (n ¼ 6e8).
Figure 6. BCG/spore-TB10.4 heterologous prime-boost did not increase long-term
survival over BCG alone. BCG immunised or placebo control mice (n ¼ 7/8) were
boosted six weeks after vaccination with two doses of either Spore-TB10.4 or Spore-
empty, one month apart. Four weeks after ﬁnal vaccination mice were challenged
intranasally with ~300 CFU of M. bovis and kept until clinical manifestations of TB
necessitated euthanisation according to a clinical scoring system. Survival was counted
as time to humane endpoint, or until the end of experiment at 318 days post-challenge.
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vaccine candidates is priming or boosting via the respiratory route
(reviewed in Ref. [28]). This poses an additional problem for
developing a vaccine for bovine TB, as unlike for humans (reviewed
in Ref. [29]), there are no reliable devices for respiratory vaccination
of cattle, compounding the ﬁnancial pressure of delivering an
effective and affordable livestock veterinary vaccine.
Inert bioparticles such as bacterial spores may represent a cost-
effective delivery vehicle: cheap to produce, easy to adsorb with
antigens and scalable [16,30]. With inherent immuno-modulatory
properties [11], HK B. subtilis spores have been shown to be effec-
tive at delivering antigens via the respiratory route, inducing pro-
tective immunity against a range of pathogens including Inﬂuenza
[13], and critically humanTB [15]. Given the versatility of spores, we
have evaluated whether parenteral delivery of spores adsorbed
with the protective antigen TB10.4 as a BCG-boost represents a
viable option for development of a cattle M. bovis vaccine. This
utilised a well-established murine M. bovis challenge model [26],
used to prioritise candidates for large animal studies.This heterologous boosting approach did not increase protective
immunity over that induced by BCG alone, as assessed by long-term
survival and bacterial load. However, bacterial load in both spleen
and lungs displayed a trend for a lower burden of ~1 log10 CFU in
spleen and ~0.5 log10 CFU in lungs, compared to BCG alone (albeit
not signiﬁcantly). It is well acknowledged that it is extremely
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ﬁcacy over that induced by BCG in such small animal models [6],
probably compounded by the inability of immune mice to perma-
nently control the challenge infection. Equally, assessment of sur-
vival of mice is rarely undertaken in evaluating TB vaccines
(reviewed in Ref. [7]) and may reﬂect a difﬁculty of discerning
improvements in efﬁcacy by this technique. Therefore, a vaccine
that may show even a small improvement over BCG is worth
further investigation and optimisation.
This trend towards lower bacterial burden associated with sig-
niﬁcant boosting of BCG-induced immune responses, but critically,
these included antigen-speciﬁc Th2 associated responses (evi-
denced by IL-4 and IL-10 production), rather than the Th1 re-
sponses considered to be an essential component of protective
immunity toTB [8], althoughwe cannot rule out that Th1 responses
may have been enhanced earlier than four weeks post-boost. This
observation may identify an opportunity to further augment pro-
tection by modulation of these responses in further work.
Although vaccine mediated induction of Th17 responses do not
necessarily impart improved protection [31], IL-17 has been
considered a key response in protection against TB [22]. Therefore,
the 10-fold increase of IL-17 production induced by the spore boost
in our study may have contributed to the increase in protective
immunity. The anatomical location of cytokine production may be
an important aspect of this, as recent studies suggest that the key
role of IL-17 is chemo-attraction of IFN-g producing cells in the
lungs [32,33]. Unfortunately, in this study we were only able to
assess systemic (spleen) rather than local (lung) responses, so this
awaits further experimentation. Encouragingly, a recent report
which correlated enhanced lung IL-17 responses with protection
also reported concurrent spleen IL-17 production [34].
Although this study did not show substantial improvement over
BCG, it was encouraging that we were able to signiﬁcantly boost
immune responses against the adsorbed antigen TB10.4 via systemic
administration in this proof of concept study. Whether the observed
Th2 bias was due to the inherent properties of the spores themselves
or the route of administration, is unclear. Few previous studies have
examined in detail the cellular immune response induced by spore
immunisation, instead relying on antibody isotype analysis
[14,35,36]; and those that have, utilised mucosal [13,15,25] or oral
[11,37] routes of immunisation. Interestingly, spores engineered to
deliver antigen to the endosomal antigen compartment via lister-
iolysin co-expression, enhanced Th1 responses, whilst unmodiﬁed
spores induced a non-polarised response (IFN-g and IL-4) [12],
although this study looked at earlier time points post-immunisation
(one week) and different assay conditions.
More recent work has demonstrated that adsorption of antigen
onto spores may in fact be sub-optimal, and that mixing antigen
with spores prior to immunisation induces a stronger adjuvant
effect and increased Th1 responses [30]. Therefore, further inves-
tigation into the suitability of spores as a subunit vaccine adjuvant
to boost BCG is warranted.
In conclusion, we have demonstrated that HK B. subtilis spores
represent a promising vaccine vehicle for boosting BCG, but that further
work is required to optimise the induction of more effective immune
responses for use as a parenteral BCG-boost vaccine for bovine TB.
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